TimesSquare Capital Management LLC Makes New $14.78 Million Investment in Kymera Therapeutics, Inc. $KYMR

TimesSquare Capital Management LLC acquired a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 189,900 shares of the company’s stock, valued at approximately $14,776,000.

Several other hedge funds also recently made changes to their positions in the company. US Bancorp DE grew its holdings in shares of Kymera Therapeutics by 9.8% during the third quarter. US Bancorp DE now owns 1,865 shares of the company’s stock worth $106,000 after purchasing an additional 166 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Kymera Therapeutics by 9.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,764 shares of the company’s stock worth $156,000 after purchasing an additional 248 shares during the last quarter. Larson Financial Group LLC grew its holdings in shares of Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after purchasing an additional 349 shares during the last quarter. Harbor Capital Advisors Inc. grew its holdings in shares of Kymera Therapeutics by 2.2% during the fourth quarter. Harbor Capital Advisors Inc. now owns 30,573 shares of the company’s stock worth $2,379,000 after buying an additional 645 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Kymera Therapeutics by 5.3% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,631 shares of the company’s stock worth $1,216,000 after buying an additional 789 shares during the last quarter.

Insider Activity at Kymera Therapeutics

In related news, COO Jeremy G. Chadwick sold 300 shares of the company’s stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $90.00, for a total value of $27,000.00. Following the sale, the chief operating officer owned 61,202 shares of the company’s stock, valued at approximately $5,508,180. This represents a 0.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Noah Goodman sold 1,347 shares of the company’s stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $90.00, for a total value of $121,230.00. Following the completion of the sale, the insider directly owned 50,195 shares in the company, valued at approximately $4,517,550. The trade was a 2.61% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 383,734 shares of company stock worth $32,454,902. 15.98% of the stock is currently owned by company insiders.

Kymera Therapeutics Trading Down 1.9%

KYMR stock opened at $78.14 on Wednesday. The firm has a 50 day moving average of $83.40 and a 200-day moving average of $78.31. Kymera Therapeutics, Inc. has a 12-month low of $28.06 and a 12-month high of $103.00. The company has a market cap of $6.43 billion, a price-to-earnings ratio of -21.89 and a beta of 2.06.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The company had revenue of $34.37 million during the quarter, compared to the consensus estimate of $8.27 million. During the same period last year, the firm earned ($0.82) EPS. The company’s revenue for the quarter was up 55.5% on a year-over-year basis. Sell-side analysts forecast that Kymera Therapeutics, Inc. will post -3.34 earnings per share for the current fiscal year.

Analyst Ratings Changes

KYMR has been the topic of a number of research reports. BTIG Research lowered their price target on Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating on the stock in a report on Thursday, February 26th. Royal Bank Of Canada reissued an “outperform” rating and set a $108.00 price target on shares of Kymera Therapeutics in a report on Thursday, February 26th. Jefferies Financial Group initiated coverage on Kymera Therapeutics in a report on Monday, March 16th. They set a “buy” rating and a $110.00 price target on the stock. Citigroup raised their price target on Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Finally, UBS Group raised their price target on Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $118.10.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.